Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Blevins

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Diabetes, Obesity & Metabolism|April 29, 2024
Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programmeRichard M Bergenstal, Athena Philis-Tsimikas, Carol Wysham, et al.
Lancet (London, England)|June 25, 2025
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trialThomas Blevins, Dominik Dahl, Federico C Pérez Manghi, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 18, 2025
Safety and Efficacy of Inhaled Technosphere<sup>®</sup> Insulin in the Postprandial Period With Modified Initial Dose ConversionChristopher Jacobson, Kevin B Kaiserman, Johanna Ulloa, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 12, 2021
American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes MellitusGeorge Grunberger, Jennifer Sherr, Myriam Allende, et al.
The New England Journal of Medicine|June 23, 2023
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with ObesitySean Wharton, Thomas Blevins, Lisa Connery, et al.
Diabetes Care|September 15, 2025
Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide LevelIrl B Hirsch, Yogish C Kudva, David T Ahn, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|May 24, 2016
CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGYVivian A Fonseca, George Grunberger, Henry Anhalt, et al.
Diabetes Technology & Therapeutics|March 18, 2025
A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 DiabetesRoy W Beck, Ryan J Bailey, Halis K Akturk, et al.
Molecular Metabolism|June 11, 2025
Methylglyoxal-induced RNA modifications decrease RNA stability and translation and are associated with type 2 diabetesEdwin De Jesus Lopez Gonzalez, Seigmund Wai Tsuen Lai, Kelani Sun, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|January 17, 2024
Beneficial Effects of Control-IQ Automated Insulin Delivery in Basal-Bolus and Basal-Only Insulin Users With Type 2 DiabetesCarol J Levy, Dan Raghinaru, Yogish C Kudva, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Diabetes, Obesity & Metabolism|April 29, 2024
Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programmeRichard M Bergenstal, Athena Philis-Tsimikas, Carol Wysham, et al.
Lancet (London, England)|June 25, 2025
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trialThomas Blevins, Dominik Dahl, Federico C Pérez Manghi, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 18, 2025
Safety and Efficacy of Inhaled Technosphere<sup>®</sup> Insulin in the Postprandial Period With Modified Initial Dose ConversionChristopher Jacobson, Kevin B Kaiserman, Johanna Ulloa, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 12, 2021
American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes MellitusGeorge Grunberger, Jennifer Sherr, Myriam Allende, et al.
The New England Journal of Medicine|June 23, 2023
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with ObesitySean Wharton, Thomas Blevins, Lisa Connery, et al.
Diabetes Care|September 15, 2025
Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide LevelIrl B Hirsch, Yogish C Kudva, David T Ahn, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|May 24, 2016
CONTINUOUS GLUCOSE MONITORING: A CONSENSUS CONFERENCE OF THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGYVivian A Fonseca, George Grunberger, Henry Anhalt, et al.
Diabetes Technology & Therapeutics|March 18, 2025
A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 DiabetesRoy W Beck, Ryan J Bailey, Halis K Akturk, et al.
Molecular Metabolism|June 11, 2025
Methylglyoxal-induced RNA modifications decrease RNA stability and translation and are associated with type 2 diabetesEdwin De Jesus Lopez Gonzalez, Seigmund Wai Tsuen Lai, Kelani Sun, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|January 17, 2024
Beneficial Effects of Control-IQ Automated Insulin Delivery in Basal-Bolus and Basal-Only Insulin Users With Type 2 DiabetesCarol J Levy, Dan Raghinaru, Yogish C Kudva, et al.
Pageof 4